Drugs / AK-1286
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06779045 | Feb 2025 → Sep 2026 overdue | — | Shanghai YingLi Pharmaceutical Co. Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AK-1286 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06779045 ↗ |
| Route | Oral | “AK-1286 PO” NCT06779045 ↗ |